Thymalfasin Accelerates COVID-19 Pneumonia Recovery Through Anti-Inflammatory Action

The global pandemic highlighted the severe and often prolonged recovery associated with COVID-19 pneumonia, frequently driven by excessive inflammation and subsequent lung damage. Patients often face extended hospital stays and persistent symptoms, underscoring an urgent need for therapies that can expedite rehabilitation and mitigate post-inflammatory complications. This study aimed to investigate whether Thymalfasin, an immunomodulatory peptide, could accelerate recovery and reduce inflammatory markers in patients suffering from COVID-19 pneumonia.

The Thymalfasin treatment group demonstrated significantly faster clinical recovery compared to the control group. The median time to clinical discharge was 14 days for Thymalfasin patients, markedly shorter than the 21 days observed in the placebo group (p<0.001). Inflammatory markers showed substantial improvement: IL-6 levels decreased by an average of 45% in the Thymalfasin group versus only 15% in controls (p<0.01). Similarly, CRP levels saw a 38% reduction in the treatment group, compared to a 10% reduction in the placebo group (p<0.005). Patient-reported fatigue scores also improved, with 85% of Thymalfasin patients reporting significant improvement by week 4, versus 55% in the control group (p<0.05). > The most impactful finding was the 33% reduction in the median duration of hospitalization for patients receiving Thymalfasin, directly translating to faster recovery and reduced healthcare burden.